Financial News

Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

45.89 -0.70 (-1.50%)

Streaming Delayed Price Updated: 2:40 PM EST, Jan 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

40 41 Next >

AstraZeneca Signals End of an Era: Formal Move to NYSE Triggers Major Index Rebalancing

Today 10:32 EST

LONDON — January 20, 2026 — In a milestone moment for global capital markets, pharmaceutical giant AstraZeneca (NYSE: AZN) has officially filed its formal notice of voluntary withdrawal from the Nasdaq...

Via MarketMinute

Topics Regulatory Compliance

GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics

Today 10:19 EST

In a bold strategic opening to the 2026 fiscal year, pharmaceutical giant GSK (NYSE:GSK) has announced a definitive agreement to acquire RAPT Therapeutics (Nasdaq:RAPT) for approximately $2.2 billion....

Via MarketMinute

Topics Intellectual Property

The Battle for the White Coat: OpenAI and Anthropic Reveal Dueling Healthcare Strategies

January 19, 2026

In the opening weeks of 2026, the artificial intelligence industry has moved beyond general-purpose models to a high-stakes "verticalization" phase, with healthcare emerging as the primary...

Via TokenRing AI

Topics Artificial Intelligence

Anthropic’s New Specialized Healthcare Tiers: A New Era for AI-Driven Diagnostics and Medical Triage

January 19, 2026

On January 11, 2026, Anthropic, the AI safety and research company, officially unveiled its most significant industry-specific expansion to date: specialized healthcare and life sciences tiers for its...

Via TokenRing AI

Topics Artificial Intelligence

The mRNA 2.0 Inflection: A Deep Dive into Moderna (MRNA) as it Faces a Critical 2026

January 16, 2026

As of January 16, 2026, Moderna, Inc. (NASDAQ: MRNA) stands at a critical crossroads. Once the poster child for the biotechnology industry’s rapid response to a global pandemic, the Cambridge-based...

Via Finterra

Topics Initial Public Offering Intellectual Property Lawsuit

Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers ↗

January 15, 2026

Via Stocktwits

Eli Lilly’s $1.2 Billion Acquisition of Ventyx Biosciences: Bridging the Gap Between Weight Loss and Chronic Inflammation

January 15, 2026

In a bold move to solidify its dominance in the cardiometabolic market, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, that it has entered into a definitive agreement to acquire Ventyx...

Via MarketMinute

Topics Intellectual Property

Why Did OCUL Stock Jump 13% In Pre-Market Today? ↗

January 15, 2026

French pharmaceutical giant Sanofi is preparing an offer to acquire the American biopharmaceutical firm, according to a report by French publication La Lettre.

Via Stocktwits

Anthropic Launches “Claude for Healthcare”: A Paradigm Shift in Medical AI Integration and HIPAA Security

January 12, 2026

On January 11, 2026, Anthropic officially unveiled Claude for Healthcare, a specialized suite of artificial intelligence tools designed to bridge the gap between frontier large language models and the...

Via TokenRing AI

Topics Artificial Intelligence

Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge

January 09, 2026

Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by...

Via MarketMinute

MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation

January 09, 2026

MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its...

Via MarketMinute

Topics Intellectual Property

BioNTech Finalizes CureVac Acquisition: A Strategic Consolidation Met with Market Skepticism

January 09, 2026

In a move that signals the end of an era for independent mRNA pioneers, BioNTech SE (Nasdaq: BNTX) has officially completed its acquisition of longtime rival CureVac N.V. (Nasdaq: CVAC). The...

Via MarketMinute

Topics Intellectual Property

Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics

January 09, 2026

Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the...

Via PredictStreet

Topics Initial Public Offering Intellectual Property

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗

January 08, 2026

Via Stocktwits

Topics Government

Trade War 2.0: Markets Braced as Trump’s 2026 Tariff ‘Salvos’ Reshape the Global Supply Chain

January 08, 2026

As of January 8, 2026, the global financial landscape is undergoing a seismic shift driven by President Trump’s latest round of "tariff salvos." These aggressive trade policies, which dominated the...

Via MarketMinute

Topics Economy Government World Trade

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge

January 07, 2026

Date: January 7, 2026 Introduction Moderna, Inc. (NASDAQ: MRNA), once the definitive poster child of the COVID-19 pandemic response, is currently undergoing one of the most significant pivots in the...

Via PredictStreet

Topics Economy Initial Public Offering Intellectual Property

The Great Unlocking: 2026 Opens with a Historic Surge in Large-Cap M&A Activity

January 06, 2026

The first week of 2026 has signaled a tectonic shift in the global financial landscape, as a wave of multi-billion dollar acquisitions has effectively ended the deal-making drought of the previous two...

Via MarketMinute

Topics Artificial Intelligence Economy Energy

Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗

January 05, 2026

Via MarketBeat

Topics Artificial Intelligence Death

BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance

January 02, 2026

In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to...

Via MarketMinute

Topics Economy Intellectual Property

Pfizer Leads New Wave Of 2026 US Drug Price Hikes Despite Trump’s Drug Cost Crackdown: Report ↗

December 31, 2025

Drugmakers are outlining 2026 list price changes, with most adjustments typically announced in January.

Via Stocktwits

Topics Economy Government

Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal

December 29, 2025

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme...

Via MarketMinute

Topics ETFs Intellectual Property

The Dynavax Turnaround: From Clinical Setbacks to a $2.2 Billion Exit

December 26, 2025

As of December 26, 2025, the biotechnology landscape is processing one of the most significant mid-cap acquisitions of the year. Dynavax Technologies Corporation (NASDAQ: DVAX) has transitioned from a...

Via PredictStreet

The Great Vaccine Consolidation: Sanofi’s $2.2 Billion Strategic Bet on Dynavax Technologies

December 25, 2025

Dateline: December 25, 2025 Introduction In a move that has sent shockwaves through the biotechnology and pharmaceutical sectors on this Christmas Day, the global vaccine landscape has been...

Via PredictStreet

Topics Economy Intellectual Property

The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax

December 25, 2025

As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ:...

Via PredictStreet

Topics Artificial Intelligence Economy Intellectual Property

Why Dynavax Stock Soared Today ↗

December 24, 2025

A healthcare titan wants to buy the biotech's vaccines.

Via The Motley Fool

Sanofi’s $2.2 Billion Strategic Pivot: Deconstructing the Dynavax Acquisition and the Future of Specialty Medicine

December 24, 2025

As of today, December 24, 2025, the global pharmaceutical landscape is witnessing a profound consolidation of power within specialty medicine and immunology. Sanofi (NASDAQ: SNY; Euronext: SAN), the...

Via PredictStreet

Topics Artificial Intelligence Economy Intellectual Property

Dynavax Technologies: Analyzing the 39% Surge and Sanofi Acquisition

December 24, 2025

Introduction On December 24, 2025, the biotechnology sector received its most significant holiday gift in years. Sanofi (NASDAQ: SNY; Euronext: SAN) announced a definitive agreement to acquire Dynavax...

Via PredictStreet

Topics Economy

Sanofi Acquires Dynavax in $2.2 Billion Christmas Eve Deal, Sending Shares Soaring

December 24, 2025

In a blockbuster conclusion to the 2025 trading year, Dynavax Technologies (NASDAQ:DVAX) saw its stock price skyrocket by nearly 40% in premarket trading this morning, December 24, 2025. The surge...

Via MarketMinute

Topics Intellectual Property

Why Did Dynavax Stock Surge 38% In Premarket Today? ↗

December 24, 2025

French drugmaker Sanofi agreed to acquire vaccine maker Dynavax in a $2.2 billion deal.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9

...

40 41 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Financial News

Sanofi - American Depositary Shares (NQ:SNY)

All News about Sanofi - American Depositary Shares

Popular Pages